These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10971448)

  • 1. Effects of normalization of GH hypersecretion on lipoprotein(a) and other lipoprotein serum levels in acromegaly.
    Maldonado Castro GF; Escobar-Morreale HF; Ortega H; Gómez-Coronado D; Balsa Barro JA; Varela C; Lasunción MA
    Clin Endocrinol (Oxf); 2000 Sep; 53(3):313-9. PubMed ID: 10971448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Lowered ghrelin levels in acromegaly—normalization after treatment].
    Kozakowski J; Rabijewski M; Zgliczyński W
    Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between insulin-like growth factor-1 levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly.
    Dobrashian RD; O'Halloran DJ; Hunt A; Beardwell CG; Shalet SM
    Clin Endocrinol (Oxf); 1993 Jun; 38(6):589-93. PubMed ID: 8334745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
    Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly.
    Parkinson C; Drake WM; Wieringa G; Yates AP; Besser GM; Trainer PJ
    Clin Endocrinol (Oxf); 2002 Mar; 56(3):303-11. PubMed ID: 11940041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients.
    Juul A; Main K; Blum WF; Lindholm J; Ranke MB; Skakkebaek NE
    Clin Endocrinol (Oxf); 1994 Jul; 41(1):85-93. PubMed ID: 7519529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy.
    Ho KY; Weissberger AJ
    Clin Endocrinol (Oxf); 1994 Jul; 41(1):75-83. PubMed ID: 8050134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
    Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LDL subfractions in acromegaly: relation to growth hormone and insulin-like growth factor-I.
    Tan KC; Shiu SW; Janus ED; Lam KS
    Atherosclerosis; 1997 Feb; 129(1):59-65. PubMed ID: 9069518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults.
    Marzullo P; Di Somma C; Pratt KL; Khosravi J; Diamandis A; Lombardi G; Colao A; Rosenfeld RG
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3001-8. PubMed ID: 11443159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
    Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor binding protein-3 levels during early and late follow-up after surgery in acromegalic patients.
    Charalampaki P; Hildebrandt G; Schaeffer HJ; Schönau E; Klug N
    Exp Clin Endocrinol Diabetes; 1998; 106(2):130-4. PubMed ID: 9628244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GH levels and insulin sensitivity are differently associated with biomarkers of cardiovascular disease in active acromegaly.
    Boero L; Manavela M; Meroño T; Maidana P; Gómez Rosso L; Brites F
    Clin Endocrinol (Oxf); 2012 Oct; 77(4):579-85. PubMed ID: 22510144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
    Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
    J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
    Freda PU; Post KD; Powell JS; Wardlaw SL
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid vascularity is increased in patients with active acromegaly.
    Bogazzi F; Manetti L; Bartalena L; Gasperi M; Grasso L; Cecconi E; Rago T; Pinchera A; Martino E
    Clin Endocrinol (Oxf); 2002 Jul; 57(1):65-70. PubMed ID: 12100071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
    Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of serum IGF-I and IGFBP-3 in growth hormone disorders in adults.
    Kim HJ; Kwon SH; Kim SW; Park DJ; Shin CS; Park KS; Kim SY; Cho BY; Lee HK
    Horm Res; 2001; 56(3-4):117-23. PubMed ID: 11847474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perioperative plasma active and total ghrelin levels are reduced in acromegaly when compared with in nonfunctioning pituitary tumours even after normalization of serum GH.
    Kawamata T; Inui A; Hosoda H; Kangawa K; Hori T
    Clin Endocrinol (Oxf); 2007 Jul; 67(1):140-4. PubMed ID: 17466003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group.
    Arosio M; Sartore G; Rossi CM; Casati G; Faglia G; Manzato E
    Atherosclerosis; 2000 Aug; 151(2):551-7. PubMed ID: 10924734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.